Abstract
Hodgkin lymphoma relapsing after autologous transplantation (autoSCT) has a dismal outcome. Allogeneic transplantation (alloSCT) using reduced intensity conditioning (RIC) is a salvage option, but its effectiveness is still unclear. To evaluate the role of RIC alloSCT, we designed a retrospective study based on the commitment of attending physicians to perform a salvage alloSCT; thus, only Hodgkin lymphoma patients having human leukocyte antigen-typing immediately after the failed autoSCT were included. Of 185 patients, 122 found an identical sibling (55%), a matched unrelated (32%) or a haploidentical sibling (13%) donor; 63 patients did not find any donor. Clinical features of both groups did not differ. Two-year progression-free (PFS) and overall survival (OS) were better in the donor group (39.3% vs 14.2%, and 66% vs 42%, respectively, P <.001) with a median follow-up of 48 months. In multivariable analysis, having a donor was significant for better PFS and OS (P <.001). Patients allografted in complete remission showed a better PFS and OS. This is the largest study comparing RIC alloSCT versus conventional treatment after a failed auto-SCT, indicating a survival benefit for patients having a donor.
| Original language | English |
|---|---|
| Pages (from-to) | 3671-3677 |
| Number of pages | 7 |
| Journal | Blood |
| Volume | 115 |
| Issue number | 18 |
| DOIs | |
| Publication status | Published - May 6 2010 |
Fingerprint
ASJC Scopus subject areas
- Hematology
- Biochemistry
- Cell Biology
- Immunology
Cite this
Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation : A retrospective study based on the time of HLA typing and donor availability. / Sarina, Barbara; Castagna, Luca; Farina, Lucia; Patriarca, Francesca; Benedetti, Fabio; Carella, Angelo M.; Falda, Michele; Guidi, Stefano; Ciceri, Fabio; Bonini, Alessandro; Ferrari, Samantha; Malagola, Michele; Morello, Enrico; Milone, Giuseppe; Bruno, Benedetto; Mordini, Nicola; Viviani, Simonetta; Levis, Alessandro; Giordano, Laura; Santoro, Armando; Corradini, Paolo.
In: Blood, Vol. 115, No. 18, 06.05.2010, p. 3671-3677.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation
T2 - A retrospective study based on the time of HLA typing and donor availability
AU - Sarina, Barbara
AU - Castagna, Luca
AU - Farina, Lucia
AU - Patriarca, Francesca
AU - Benedetti, Fabio
AU - Carella, Angelo M.
AU - Falda, Michele
AU - Guidi, Stefano
AU - Ciceri, Fabio
AU - Bonini, Alessandro
AU - Ferrari, Samantha
AU - Malagola, Michele
AU - Morello, Enrico
AU - Milone, Giuseppe
AU - Bruno, Benedetto
AU - Mordini, Nicola
AU - Viviani, Simonetta
AU - Levis, Alessandro
AU - Giordano, Laura
AU - Santoro, Armando
AU - Corradini, Paolo
PY - 2010/5/6
Y1 - 2010/5/6
N2 - Hodgkin lymphoma relapsing after autologous transplantation (autoSCT) has a dismal outcome. Allogeneic transplantation (alloSCT) using reduced intensity conditioning (RIC) is a salvage option, but its effectiveness is still unclear. To evaluate the role of RIC alloSCT, we designed a retrospective study based on the commitment of attending physicians to perform a salvage alloSCT; thus, only Hodgkin lymphoma patients having human leukocyte antigen-typing immediately after the failed autoSCT were included. Of 185 patients, 122 found an identical sibling (55%), a matched unrelated (32%) or a haploidentical sibling (13%) donor; 63 patients did not find any donor. Clinical features of both groups did not differ. Two-year progression-free (PFS) and overall survival (OS) were better in the donor group (39.3% vs 14.2%, and 66% vs 42%, respectively, P <.001) with a median follow-up of 48 months. In multivariable analysis, having a donor was significant for better PFS and OS (P <.001). Patients allografted in complete remission showed a better PFS and OS. This is the largest study comparing RIC alloSCT versus conventional treatment after a failed auto-SCT, indicating a survival benefit for patients having a donor.
AB - Hodgkin lymphoma relapsing after autologous transplantation (autoSCT) has a dismal outcome. Allogeneic transplantation (alloSCT) using reduced intensity conditioning (RIC) is a salvage option, but its effectiveness is still unclear. To evaluate the role of RIC alloSCT, we designed a retrospective study based on the commitment of attending physicians to perform a salvage alloSCT; thus, only Hodgkin lymphoma patients having human leukocyte antigen-typing immediately after the failed autoSCT were included. Of 185 patients, 122 found an identical sibling (55%), a matched unrelated (32%) or a haploidentical sibling (13%) donor; 63 patients did not find any donor. Clinical features of both groups did not differ. Two-year progression-free (PFS) and overall survival (OS) were better in the donor group (39.3% vs 14.2%, and 66% vs 42%, respectively, P <.001) with a median follow-up of 48 months. In multivariable analysis, having a donor was significant for better PFS and OS (P <.001). Patients allografted in complete remission showed a better PFS and OS. This is the largest study comparing RIC alloSCT versus conventional treatment after a failed auto-SCT, indicating a survival benefit for patients having a donor.
UR - http://www.scopus.com/inward/record.url?scp=77952574651&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952574651&partnerID=8YFLogxK
U2 - 10.1182/blood-2009-12-253856
DO - 10.1182/blood-2009-12-253856
M3 - Article
C2 - 20220116
AN - SCOPUS:77952574651
VL - 115
SP - 3671
EP - 3677
JO - Blood
JF - Blood
SN - 0006-4971
IS - 18
ER -